Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult male aged 18-45 years.~* Normal medical history and physical examination. Minor physical ailments e.g. Fungal skin infections, will not be sufficient to define a physical examination as abnormal.~* Normal urine dipstick, blood count, liver enzymes, and creatinine~* Frequency \<4 SFU per/well/3x105 PBMC as determined by ELISPOT with ESAT6/CFP-10 antigens and less than 100 SFU per/well/1x106 PBMC as determined by ELISPOT with PPD.~* Mantoux negative (0.0 mm induration).~* Normal Chest X-ray.~* Willing to donate blood samples as required by the protocol~Exclusion Criteria:~* Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease or neurological illness.~* Any clinical evidence of immunosuppression such as oral candida, stomatitis, aphthous or septic ulceration, septic skin lesions or any clinical or laboratory evidence of infection or immunocompromise.~* History of splenectomy~* Haematocrit of less than 30%~* Serum creatinine concentration \>130mmol~* Serum ALT concentration \>80IU/L~* Blood transfusion within one month of the beginning of the study~* History of vaccination with any previous experimental poxvirus vaccine~* Administration of any other vaccine or immunoglobulin within two weeks before or two weeks after vaccination.~* Positive HIV antibody test, evidence of HBV (Hepatitis B vaccination is not an exclusion criteria)..~* Current participation in another clinical trial, or within 12 weeks of this study~* Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.~* Likelihood of travel away from the study area for the duration of the study~* Untreated malaria infection

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).